uniQure (NASDAQ:QURE) Director Rachelle Suzanne Jacques Sells 1,993 Shares of Stock

uniQure N.V. (NASDAQ:QURE) Director Rachelle Suzanne Jacques sold 1,993 shares of the stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $27.06, for a total transaction of $53,930.58. Following the transaction, the director owned 33,903 shares in the company, valued at approximately $917,415.18. This trade represents a 5.55% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

uniQure Stock Performance

Shares of QURE opened at $27.57 on Friday. The company’s fifty day moving average is $22.52 and its 200-day moving average is $21.80. uniQure N.V. has a 12 month low of $8.73 and a 12 month high of $71.50. The firm has a market cap of $1.74 billion, a price-to-earnings ratio of -7.92 and a beta of 0.98. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.03. The business had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. Equities analysts expect that uniQure N.V. will post -3.64 EPS for the current fiscal year.

Institutional Trading of uniQure

A number of hedge funds have recently bought and sold shares of QURE. Torren Management LLC bought a new stake in uniQure in the 4th quarter valued at $28,000. Jones Financial Companies Lllp raised its stake in shares of uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 509 shares in the last quarter. IFP Advisors Inc acquired a new position in shares of uniQure in the 4th quarter valued at $48,000. Smartleaf Asset Management LLC acquired a new position in shares of uniQure in the 4th quarter valued at $48,000. Finally, CIBC Private Wealth Group LLC acquired a new position in shares of uniQure in the 3rd quarter valued at $50,000. 78.83% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on QURE. Sanford C. Bernstein downgraded shares of uniQure to a “market perform” rating in a report on Tuesday, March 3rd. The Goldman Sachs Group upped their price objective on shares of uniQure from $9.00 to $10.00 and gave the stock a “neutral” rating in a report on Monday, April 20th. Wells Fargo & Company raised shares of uniQure from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $15.00 to $60.00 in a report on Monday, March 9th. Leerink Partners reaffirmed an “outperform” rating and set a $35.00 price objective on shares of uniQure in a report on Monday, March 2nd. Finally, TD Cowen reaffirmed a “buy” rating on shares of uniQure in a report on Tuesday, March 3rd. Ten equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $42.83.

Key Headlines Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Negative Sentiment: A cluster of insiders sold shares in recent filings, including directors Robert Gut, Madhavan Balachandran, Rachelle Suzanne Jacques, Jack Kaye, Leonard E. Post, Jeremy P. Springhorn, and David D. Meek, along with insider Kylie O’keefe. The transactions totaled a meaningful reduction in ownership across the group, increasing focus on insider confidence. Article: UniQure Rocked by Wave of High-Level Insider Stock Sales
• Neutral Sentiment: Several of the sales were made under pre-arranged Rule 10b5-1 trading plans, which can lessen the bearish signal because the trades may have been scheduled in advance rather than reflecting a sudden change in outlook.
• Neutral Sentiment: The stock has already been trending above its 50-day and 200-day moving averages, so some of the selling may simply reflect profit-taking after a strong move rather than a deterioration in the company’s fundamentals.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.